Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that argenx has identified four new targets under their global collaboration and license agreement. This agreement grants argenx exclusive access to Halozyme’s ENHANZE®…
GigaGen Inc., a biotechnology firm specializing in innovative antibody treatments for immunodeficiencies, infectious diseases, and cancers resistant to checkpoint inhibitors, has announced a new contract awarded by the Biomedical Advanced…
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and mAbxience, a majority-owned group by Fresenius Kabi with partial ownership from Insud Pharma, have…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) has announced the conclusion of a sales partnership agreement with Nxera Pharma Japan Co., Ltd. (hereafter…
Allergan Aesthetics, a part of AbbVie, has announced its sixth consecutive year of partnering with Girls Inc. to encourage high school and college girls’ interest in STEM (science, technology, engineering,…
Gilead Sciences, Inc. (Nasdaq: GILD) has announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and distribute generic lenacapavir in 120 high-incidence, resource-limited countries,…
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for the treatment of adult patients with resectable non-small cell lung…
Amgen (NASDAQ: AMGN) has teamed up with actress, producer, and entrepreneur La La Anthony to highlight her personal experience with plaque psoriasis and inspire others to have open conversations with…
AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab…
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with…
Eli Lilly and Company (NYSE: LLY) announced a significant $4.5 billion investment to establish the Lilly Medicine Foundry, a state-of-the-art facility for advanced manufacturing and drug development. This innovative center…
AIVITA Biomedical, Inc., a biotech firm focused on pioneering stem cell applications, has announced a licensing agreement with LevEllis, a global skincare retailer. This partnership grants LevEllis the exclusive worldwide…